Log in or register to see all Alerts
New HTA Decisions in England
June 2020
Drug name
CYRAMZA® (ramucirumab)
Company
Eli Lilly and Company Ltd
Decision date
30/06/2020
Therapeutic area
Cancer
Therapeutic sub area
Lung cancer
Decision
Not recommended
Indication
Untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer.
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer, because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.